会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • System and method for generating molybdenum-99 and metastable technetium-99, and other isotopes
    • 用于生成钼-99和亚稳锝-99以及其他同位素的系统和方法
    • US20150179290A1
    • 2015-06-25
    • US12928227
    • 2010-12-07
    • James E. Clayton
    • James E. Clayton
    • G21G1/00G21G1/02
    • G21G1/0005G21G1/001G21G1/02G21G1/06G21G1/10G21G1/12G21G2001/0036G21G2001/0042
    • An accelerator based systems are disclosed for the generation of isotopes, such as molybdenum-98 (“99Mo”) and metastable technetium-99 (“99mTc”) from molybdenum-98 (“98Mo”). Multilayer targets are disclosed for use in the system and other systems to generate 99mTc and 98Mo, and other isotopes. In one example a multilayer target comprises a first, inner target of 98Mo surrounded, at least in part, by a separate, second outer layer of 98Mo. In another example, a first target layer of molybdenum-100 is surrounded, at least in part, by a second target layer of 98Mo. In another example, a first inner target comprises a Bremsstrahlung target material surrounded, at least in part, by a second target layer of molybdenum-100, surrounded, at least in part, by a third target layer of 98Mo.
    • 公开了一种用于产生钼-98(“99Mo”)和亚稳态锝-99(“99mTc”)的钼同位素(“98Mo”)的同位素的加速器系统。 公开了多层目标用于系统和其他系统中以产生99mTc和98Mo以及其他同位素。 在一个示例中,多层靶包括98Mo的第一内部目标,至少部分由98Mo的单独的第二外层包围。 在另一个实例中,钼-100的第一目标层至少部分地被98Mo的第二目标层包围。 在另一个示例中,第一内部目标包括至少部分地被第一靶标的钼-100包围的Bre致射线靶材料,至少部分由98Mo的第三目标层包围。
    • 10. 发明申请
    • METHOD AND APPARATUS FOR THE PRODUCTION OF LEAD 212 FOR MEDICAL USE
    • 用于生产用于医疗用途的引线212的方法和装置
    • US20150170776A1
    • 2015-06-18
    • US14402325
    • 2013-05-23
    • AREVA MED SAS
    • Julien TorguePatrick MaquaireJohn YoungGilbert AndreolettiPatrick Bourdet
    • G21G1/00C22B13/06C22B13/02A61K51/12C22C11/00
    • G21G1/0005A61K51/12C22B13/02C22B13/06C22C11/00G21G4/08G21G2001/0094
    • The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution A1, characterised in that the lead (212) contained in the aqueous solution A1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column. The invention also relates to an apparatus specially designed for automated implementation in a closed system of said method. It further relates to lead (212) produced by means of this method and this apparatus. Applications: manufacture of radiopharmaceuticals based on lead (212), useful in nuclear medicine for the treatment of cancers, particularly by a-radioimmunotherapy, or for medical imaging, in both humans and animals.
    • 本发明涉及一种用于制备用于医疗用途的铅(212)的方法。 该方法包括在包括固体介质的发生器中通过镭(224)的衰变产生铅(212),镭(224)结合到该固体介质上,随后在发生器中从引线(212)中提取铅 水溶液A1的形式,其特征在于,通过柱上的液相色谱法,包含在水溶液A1中的铅(212)从也含在所述水溶液中的放射性和化学杂质中纯化。 本发明还涉及专门设计用于所述方法的封闭系统中的自动化实施的装置。 它还涉及通过该方法和该装置产生的引线(212)。 应用:在人类和动物中制造基于铅(212)的放射性药物,用于治疗癌症,特别是放射免疫疗法或用于医学成像的核医学。